2023年12月2日～2023年12月8日の間に収集した論文情報を追加しました。
1. Unpacking adverse events and associations post COVID-19 vaccination: a deep dive into vaccine adverse event reporting system data.
COVID-19ワクチン接種に関連する副反応をVAERSデータから分析
対象DB：FAERS,VAERS
2. Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases.
抗てんかん薬と男性特有の合併症「ピリオニスム」の関連性を検証
対象DB：FAERS
3. Optimizing Signal Management in a Vaccine Adverse Event Reporting System: A Proof-of-Concept with COVID-19 Vaccines Using Signs, Symptoms, and Natural Language Processing.
COVID-19ワクチンの副反応報告が急増し、VAERSの信頼性に影響
対象DB：FAERS,VAERS
4. Evaluation of cardiotoxicity of anthracycline-containing chemotherapy regimens in patients with bone and soft tissue sarcomas: A study of the FDA adverse event reporting system joint single-center real-world experience.
抗がん剤による心毒性の調査
対象DB：FAERS
5. Incidence of Anaphylaxis to YF-VAX(R) Yellow Fever Vaccination: A Retrospective Evaluation of Vaccine Adverse Event Reports 1999-2018.
黄熱病ワクチン接種後のアナフィラキシー発生率を調査
対象DB：FAERS,VAERS
6. A Pharmacovigilance Study of Drug-Induced Glaucoma Utilizing the Japanese Adverse Event Reporting System.
薬剤の副作用としての緑内障を調査
対象DB：FAERS,JADER
7. Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA adverse event reporting system from 2004 to 2022.
抗生物質と抗生物質関連下痢のリスクを検証
対象DB：FAERS
8. Thyroid hyperplasia and neoplasm adverse events associated with GLP-1 receptor agonists in FDA Adverse Event Reporting System.
GLP-1の安全性に関する18万件以上の報告を分析
対象DB：FAERS
9. Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS).
抗がん剤や抗糖尿病薬など264種類の薬物が急性膵炎と関連しているリスク因子の研究
対象DB：FAERS
10. Psychotherapeutic drug-induced life-threatening arrhythmias: A retrospective analysis using the Japanese adverse drug event report database.
日本の臨床において、精神疾患治療薬が危険な心室性不整脈と関連している可能性
対象DB：JADER
11. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK.
クロザピン関連の致命的な副作用報告の研究
対象DB：VigiBase
12. Drug-induced tumoral disease: A global pharmacovigilance database analysis.
VigiBaseでがんと関連する薬物の頻度を調査
対象DB：VigiBase
13. The Relationship Between Preoperative Frailty Risk as Assessed by the Hospital Frailty Risk Score and the Outcome at Discharge in Coronary Artery Bypass Grafting (CABG) Patients: A Retrospective Observational Study Using the Diagnosis Procedure Combination Database.
冠動脈バイパス手術後のアウトカムとHFRSに基づく虚弱リスクとの関連性
対象DB：DPC
14. Therapeutic interventions and the length of hospital stay for pediatric patients with COVID-19: a multicenter cohort study.
COVID-19初期の小児患者の特徴や治療アプローチの研究
対象DB：DPC
15. Association Between Intraoperative Landiolol Use and In-Hospital Mortality After Coronary Artery Bypass Grafting: A Nationwide Observational Study in Japan.
冠動脈バイパス手術中の輸液ランジオロール塩酸塩の使用と、入院中の死亡率の関連
対象DB：DPC
16. QRISK3 underestimates the risk of cardiovascular events in patients with COPD.
慢性閉塞性肺疾患の循環器疾患リスクの研究
対象DB：CPRD
17. Health-care resource use among patients who use illicit opioids in England, 2010-20: A descriptive matched cohort study.
イギリスの違法オピオイド使用者は一般人よりも医療機関を頻繁に利用
対象DB：CPRD
18. Incidence and individual risk prediction of post-COVID-19 cardiovascular disease in the general population: a multivariable prediction model development and validation study.
COVID-19感染後の心血管疾患の発生率を評価
対象DB：CPRD
19. Conversion of CPRD AURUM Data into the OMOP Common Data Model.
CPRD AURUMデータをOMOP CDMに変換、データ損失を最小限に抑え、データ解析を実施
対象DB：CPRD
20. Association Between Diseases and Symptoms Diagnosed in Primary Care and the Subsequent Specific Risk of Multiple Sclerosis.
多発性硬化症の前駆症状と自己免疫疾患の研究
対象DB：THIN